Caitlin E. Olwell

I'll research this attorney's background and verify the tracked case information.

Let me verify her current title and the tracked case details more precisely.

Caitlin E. Olwell — Patent Litigation Practice Summary

Specialty / focus. Olwell is an IP litigator whose practice centers on patent and trade secret disputes in the medical device and pharmaceutical/life sciences sectors, with additional experience in consumer products and communications. Her firm bio and representative matters span negative-pressure wound therapy and wound dressings, spinal cord stimulation leads, shoulder implant components and reamers, nasal spray delivery devices, fluid dispenser systems, and ANDA/pharmaceutical litigation. Her technical background is life-sciences rather than engineering: a B.A. in biology (Colgate) and, before law school, high school biology/environmental science teaching. Nothing in the tracked matters or firm materials indicates Wi-Fi/standards-essential-patent or software work; the closest "communications" matter is deaf/hard-of-hearing relay services (Sorenson).

Side preference. She works both sides. Akin's own bio states she represents "both plaintiffs and defendants" in patent and trade secret disputes, and her representative matters include both patent owners (ANDA plaintiffs) and accused infringers (defendants). The two tracked appearances are drawn from a single underlying dispute, Wound Healing Technologies Corp. v. Solventum Corporation (No. 6:24-cv-589, W.D. Tex., filed Nov. 15, 2024), where Akin represents Solventum. The tracker labels one entry plaintiff-side and the other defendant-side; the most likely reconciliation is that one entry reflects the district court caption (Solventum as defendant) and the other the parallel IPR caption, Solventum Corp. v. Wound Healing Technologies Corp., IPR2025-01042 (Solventum as petitioner/first-named party). On the public record, her client is on the defense/challenger side in both—not NPE-side work. Because both tracked entries trace to one dispute, the 1-1 plaintiff/defendant split should not be read as a balanced book of NPE and defense work.

Firm context. She is at Akin Gump Strauss Hauer & Feld LLP ("Akin"), New York office. Current firm directory lists her as Partner (earlier Akin publications and filings, including her October 2025 IPR declaration, describe her as counsel; the partner title appears in the most recent directory listings). Before Akin she worked at a national law firm in New York and clerked for the Hon. Charles F. Lettow at the U.S. Court of Federal Claims.

Notable matters and PTAB/IPR work. She was on the Akin trial team that obtained a $20 million Delaware jury verdict for Boston Scientific against Nevro in October 2021 (willful infringement of spinal cord stimulation lead patents; the series settled in August 2022), where she conducted direct and cross-examinations. She was also part of the Akin team representing Sorenson Communications/CaptionCall against Ultratec/CapTel, which won affirmance of nine PTAB decisions at the Federal Circuit before certiorari was denied, and the team that invalidated patents in parallel IPRs for 3M/Merck against Aptar. She is an active PTAB practitioner: member of the PTAB Bar Association, author of Akin's "Overlooked PTAB Cases" Law360 series and numerous PTAB/IPR client alerts, and declarant in the Solventum IPR. In the Wound Healing matter, the district court stayed the litigation pending the Board's institution decision, and the PTAB instituted IPR2025-01042.

Bar / education. Admitted in New York and before the U.S. Patent and Trademark Office; J.D., Northwestern University School of Law (cum laude, 2014).

Sourcing note: Bar admissions, education, clerkship, firm and representative matters come from Akin's official bio, its press releases, and USPTO/PTAB filings. The plaintiff/defendant attribution within the tracked Solventum dispute is inferred from court and PTAB records rather than confirmed by the tracker, and the current title (partner vs. counsel) is inconsistent across sources.